Tuesday, October 3, 2023
Tuesday, October 3, 2023

Contact: 561.316.3330

Novotech Partners with South Korea’s Pusan National University Hospital

June 18, 2020

Novotech, the leading Asia-Pacific biotech specialist CRO, has partnered with South Korea’s world-class Pusan National University Hospital (PNUH).

Novotech notes the Partnership is designed to further support Novotech’s biotech clients run their clinical trials in the region.

Dr. Jeong Zoo Lee, the President of PNUH, said: “The PNUH site team and Novotech have worked together on a number of studies already. We have progressed to a formal agreement to support Novotech’s biotech clients across all clinical research and patient recruitment areas.

“We are pleased to partner with a regional CRO leader with such an outstanding reputation internationally,” said Dr. Lee.

Dr. Yooni Kim, Executive Director, Asia Operations said: “Novotech was very pleased to establish a Partnership with PNUH, which has completed more than 340 clinical trials and is ranked 7th in terms of number of clinical trials in South Korea *GlobalData.

“The PNUH site offers biotechs quality infrastructure, world-class medical and hospital facilities, as well as South Korea’s supportive rapid start-up environment. The main therapeutic areas at PNUH have been oncology, infectious disease, cardiovascular and gastrointestinal,” said Dr. Kim.

Novotech now has over 20 significant Partnerships with some of the leading medical institutions in the region. The Partnership Program is strategically designed to deliver unparalleled access to quality investigators, KOLs, and up to 4 million patients for its international biotech clients.

SourceNovotech
Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Ariceum Therapeutics’ Targeted Radiopharmaceutical 177Lu-satoreotide Exhibits Promising Clinical Response and Good Tolerability Profile in Patients with Advanced Neuroendocrine Tumours

Satoreotide combines Ariceum’s proprietary peptide satoreotide - a first-in-class and best-in-class antagonist of the somatostatin receptor 2 (SSTR2) - with the radioactive isotope ‘payload’ 177Lutetium. SSTR2 is a cell surface protein often overexpressed in certain cancers, including NETs and small cell lung cancer (SCLC).

New Hot Start Isothermal Mixes Boost Sensitivity, Specificity, and Speed of DNA Target Detection

Isothermal mixes are important in a range of isothermal amplification applications, including whole genome amplification, point-of-care assay development and testing, and strand displacement amplification for synthetic biology. However, a common issue with isothermal mixes is non-specific amplification — where primers bind to unintended DNA targets — because amplification often takes place at a fixed temperature which may favour non-specific primer interactions, contrary to PCR. Isothermal mixes can also lead to primer dimer formation, where primers associate with each other and are extended by the polymerase.

Branded Legacy Invests Heavily in Innovation and Growth with $540,000 Expansion

This strategic initiative underscores Branded Legacy's unwavering commitment to innovation, quality, and customer satisfaction. The expansion project is set to infuse over $500,000 worth of inventory into the company, reinforcing its position as a leader in the market.

Cue Biopharma Completes Patient Enrollment in Ph1b Head & Neck Cancer Trial

“Completing the enrollment of the recommended phase 2 dose patient expansion cohort is an important milestone as the data from this trial guides further development plans and associated discussions with the Food and Drug Administration (FDA),” said Daniel Passeri, chief executive officer of Cue Biopharma.

Revvity Expands Access to Base Editing Technology with Aim to Accelerate Discovery to Cure

Michelle Fraser, head of cell and gene therapy at Revvity, underscores the importance of providing broad access to this technology: "Base editing has been extensively demonstrated in numerous studies to safely and precisely control the correction of single base changes at multiple target sites, simultaneously. This streamlined approach simplifies complex multi-gene editing, holding great promise for the development of new cell therapies targeting rare inherited genetic diseases, cancer, and in the creation of universal donor cells as the foundation of allogeneic cell therapies."

By using this website you agree to accept Medical Device News Magazine Privacy Policy